Home / Health / New Drug Targets 5 Receptors for Major Weight Loss
New Drug Targets 5 Receptors for Major Weight Loss
14 May
Summary
- Experimental drug combines hormones with PPAR activity.
- Drug acts as a 'Trojan horse' for targeted cellular delivery.
- Mouse models show greater weight loss than existing drugs.
An experimental drug, identified as GLP-1-GIP-Lani, is emerging as a promising candidate in the fight against obesity and diabetes. Developed by researchers at Helmholtz Munich, this drug functions as a quintuple agonist, targeting five receptor systems simultaneously. Its innovative design utilizes a 'Trojan horse' mechanism, where incretin hormones deliver PPAR activity directly into cells.
This targeted approach allows for a significantly lower dosage, which may mitigate common side effects associated with weight-loss medications. Studies in mouse models, including those with induced obesity and insulin resistance, revealed that the drug surpassed GLP-1 and GIP alone, and even semaglutide, in reducing body weight, food intake, and blood sugar levels. Researchers are now focused on optimizing this approach for human clinical trials.
